PVR (KM) M=Ekskluderede M=Failure

PVR (KM) M=Excluded M=Failure

Den gennemsnitlige ændring fra baseline i pulmonal vaskulær modstand (PVR) var -122 dyn. sek/cm5, for sildenafil 20 mg 3 gange dagligt.

The mean change from baseline in pulmonary vascular resistance (PVR) was ­122 dyne. sec/cm5 for sildenafil 20 mg three times a day.

Den gennemsnitlige ændring fra baseline i pulmonal vaskulær modstand (PVR) var - 122 dyn. sek/ cm5, for sildenafil 20 mg 3 gange dagligt.
http://www.emea.europa.eu/

The mean change from baseline in pulmonary vascular resistance (PVR) was – 122 dyne. sec/ cm5 for sildenafil 20 mg three times a day.
http://www.emea.europa.eu/

-0, 5% (-3, 2% til 2, 2%) 0, 6% (-2, 3% til 5, 2%) -0, 7% (-6, 4% til 6, 4%) PVR (KM):

-0.5% (-3.2% to 2.2%) 0.6% (-2.3% to 5.2%) -0.7% (-6.4% to 6.4%) PVR (KM):

Det primære slutpunkt var den procentvise ændring fra baseline i PVR og ændring fra baseline ved tilbagelagt afstand ved 6 minutters gang i forhold til 6. måned versus placebo.
http://www.emea.europa.eu/

The co-primary endpoints were percentage change from baseline in PVR and change from baseline in 6-minute walk distance to Month 6 versus placebo.
http://www.emea.europa.eu/

Den procentvise reduktion i PVR (11, 2%) for sildenafil 20 mg var efter en 12 ugers periode proportionelt større end reduktionen i systemisk vaskulær modstand (SVR) (7, 2%).
http://www.emea.europa.eu/

The percent reduction at 12 weeks for sildenafil 20 mg in PVR (11.2%) was proportionally greater than the reduction in systemic vascular resistance (SVR) (7.2%).
http://www.emea.europa.eu/

I disse tilfælde er den pulmonale, vaskulære modstand (resistance) (PVR) stor, hvilket resulterer i hypoxæmi sekundært til højre/venstre-shuntning af blodet gennem den åbentstående ductus arteriosus og foramen ovale.

In these states, pulmonary vascular resistance (PVR) is high, which results in hypoxemia secondary to right-to-left shunting of blood through the patent ductus arteriosus and foramen ovale.

Når de to strata blev analyseret separat, var responsraterne i det stratum med tidligere proteasehæmmer- behandling numerisk lavere for de patienter, der skiftede til Atripla [92, 4% versus 94, 0% for PVR (sensitivitetsanalyse) for henholdsvis Atripla - og SBR- patienter (SBR, stayed on their baseline regimen); en forskel (95% CI) på - 1, 6% (- 10, 0%; 6, 7%)].
http://www.emea.europa.eu/

When the two strata were analysed separately, response rates in the stratum with prior PI-treatment were numerically lower for patients switched to Atripla [92.4% versus 94.0% for the PVR (sensitivity analysis) for Atripla and SBR patients respectively; a difference (95%CI) of -1.6% (-10.0%, 6.7%)].
http://www.emea.europa.eu/